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INTRODUCTION
Renal cell carcinoma (RCC) represents the most common
cancer of kidney and accounts for approximately 3% of all
adult malignancies in western countries (1). RCC remains
primarily a surgical disease requiring early diagnosis to opti-
mize the opportunity for cure. The treatment for patients
with RCC who have no clinical signs of distant metastases is
radical nephrectomy. However, metastases occur in approxi-
mately 30% of these patients, usually within 1 yr. Moreover
30% of patients already have metastases at the time of pre-
sentation (2), and in this situation neither chemotherapy nor
radiation therapy is effective. Despite the lack of an effective
systemic therapy, a small but significant improvement in over-
all 5-yr survival has been noted due to early detection and
advances in surgical management of the disease (3).
A number of investigations have recently undertaken to
search for a protein marker for RCC, which can be used for
early diagnosis, staging, detection of occult metastatic dis-
ease, and to monitor the response to treatment. However,
they have been shown to be either nonspecific or insensitive
(4). Proteins are key materials to understand cellular functions
and disease process, such as tumorigenesis, tumor growth
and metastases. Thus, it is expected that protein expression
would differ between normal kidney tissue and homologous
RCC tissue. Many investigators are currently working on the
characterization of RCC using proteome-based techniques.
This technique has been shown to be a useful tool to identi-
fy novel proteins for diagnosis and prognosis of malignant
disease including colorectal carcinoma (5), lung (6), and breast
cancer (7). In RCC, Sarto et al. (8) reported a number of poly-
peptides differentially expressed in RCC by comparing 2-
dimensional electrophoresis patterns of whole normal kid-
ney epithelium and RCC tissue.
In this study, we prepared proteins from the RCC tissue
and the homologous normal kidney tissue, and analyzed a
number of proteins to isolate and identify tumor-specific pro-
teins of RCC by two-dimensional gel electrophoresis.
MATERIALS AND METHODS
Clinical sample
The tissue samples of conventional RCC and the surround-
ing non-cancerous kidney tissues were prepared from surgi-
cal specimens of 7 patients after radical nephrectomy. The
study protocol was approved by the Human Subject Research
Committee of the Gyeongsang National University. The speci-
mens were examined by a pathologist. Part of the sample was
immediately frozen in liquid nitrogen and stored at -80℃
until use. The remaining parts of the samples were taken and
processed for histological examination. The tumor stage was
determined according the 1997 TNM staging system (9).
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Identification of Proteins Differentially Expressed in the Conventional
Renal Cell Carcinoma by Proteomic Analysis
Renal cell carcinoma (RCC) is one of the most malignant tumors in urology, and
due to its insidious onset patients frequently have advanced disease at the time of
clinical presentation. Thus, early detection is crucial in management of RCC. To
identify tumor specific proteins of RCC, we employed proteomic analysis. We pre-
pared proteins from conventional RCC and the corresponding normal kidney tis-
sues from seven patients with conventional RCC. The expression of proteins was
determined by silver stain after two-dimensional polyacrylamide gel electrophore-
sis (2D-PAGE). The overall protein expression patterns in the RCC and the normal
kidney tissues were quite similar except some areas. Of 66 differentially expressed
protein spots (p<0.05 by Student t-test), 8 different proteins from 11 spots were
identified by MALDI-TOF-MS. The expression of the following proteins was repress-
ed (p<0.05); aminoacylase-1, enoyl-CoA hydratase, aldehyde reductase, tropo-
myosin  -4 chain, agmatinase and ketohexokinase. Two proteins, vimentin and  -1
antitrypsin precursor, were dominantly expressed in RCC (p<0.05).
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Sample preparation for 2-demensional gel electrophoresis
The frozen kidney tissues were washed several times with
phosphate-buffered saline (pH 7.2) to remove cell debris and
any remaining blood. The samples were homogenized in lysis
buffer (0.3 g tissue/l mL buffer) (8 M urea, 2% CHAPS, am-
pholytes and 1 mM PMSF), and were centrifuged at 100,000
×g for 10 min at 4℃. The resulting supernatant was kept
at -80℃until use. The total protein concentration was deter-
mined by the Bradford method using bovine serum albumin
as a standard (10). 
Two-dimensional gel electrophoresis
The IPG gel strips (Bio-Rad, CA, U.S.A.) were rehydrat-
ed in a swelling solution [7 M urea, 2% CHAPS, 100 mM
dithiothreitol, 0.5% IPG buffer (Amersham biosciences), and
bromophenol blue] that contained 50  g (for silver staining)
or 500  g (for Coomassie staining) proteins for 12 hr at 20℃.
Isoelectric focusing (IEF) was performed on immobilized pH
gradients (IPG, pH 4-7, 18cm) at 20℃ in three steps: at
250 V (15 min), 10,000 V (3 hr), and then for 40,000 Vh
using Protean IEF Cell (Bio-Rad, CA, U.S.A.). After the IEF
procedure, the strips were equilibrated with a buffer contain-
ing 50 mM Tris-HCl, pH 8.8, 6 M urea, 30% glycerol, 2%
SDS, and 1% dithiothreitol for 15 min as a first step, and
with 2.5% iodoacetamide instead of dithiothreitol for another
15 min as a second step. For SDS gel electrophoresis, a 7.5-
17.5% gradient SDS gel was prepared, then an equilibrated
IPG gel strip was laid on top of the gel and was covered with
0.5% agarose solution. Gel electrophoresis was carried out
at 16℃ at 5 mA/cm (constant current) for 1 hr, and then at
10 mA/cm until the bromophenol blue reached the bottom
of the gel. For silver staining, the gel was fixed in a solution
(50% methanol and 12% acetic acid) for 1.5 hr; washed in
50% ethanol twice for 30 min each time, and then treated
with 0.2% sodium sulfoxide for 1 min. After washing with
deionized water 3 times for 1 min each, the gel was impreg-
nated in a solution (0.2% silver nitrate and 0.75 mL/L for-
maldehyde) for 20 min and washed twice in water. The gel was
developed in a solution (2% sodium bicarbonate, 0.0004%
sodium sulfoxide, and 0.5 mL/L formaldehyde), and the reac-
tion was stopped by adding 1% acetic acid at the designated
time point. For Coomassie blue staining, the gel was soaked
in a fixation solution (30% ethanol, and 2% phosphoric acid)
for 30 min, then in 2% phosphoric acid for 20 min, and equi-
librated in a solution (2% phosphoric acid, 18% ethanol, and
15% ammonium sulfate) for 30 min. The gel was stained in
the equilibration solution containing Coomassie Brilliant
Blue G-250 for overnight.
Image analysis and protein identification
The protein patterns in the gel were recorded as digitalized
images using a high-resolution scanner (GS-710 Calibrated
Imaging Densitometer, Bio-Rad, CA, U.S.A.). Four gels were
running for each sample. The scanned gel image was analyzed
using a standard protocol for PDQuest software (Bio-Rad,
Hercules, CA, U.S.A.). Differentially expressed proteins (p<
0.05 by Student’s t-test) were identified in each patient’s tumor
sample compared to the corresponding normal kidney sam-
ple to form eight independent analyses. Inter-individual com-
parisons were then made by comparison of reference gels and
protein spots found to be significantly higher or lower in all
tumor samples compared to corresponding normal kidney
samples. For protein identification, we used a Voyager -DETM
(delayed extraction) STR biospectrometry workstation (Applied
Biosystems, Forster city, CA, U.S.A.) for MALDI-TOF mass
spectrometry. The gel pieces containing the desired protein
spots were excised, washed and digested in gel with trypsin
(sequencing grade, Boehringer Mannheim) (11). The result-
ing peptides were then processed for MALDI-TOF/MS. The
search for protein identity was performed with reference to
the public sequence databases (SWISS-PROT or NCBI) using
MS-Fit (http://prospector.ucsf.edu/ucsfhtml13.4/msfit.htm).
The data were analyzed using Student’s t-test. Statistical sig-
nificance was set at p<0.05.
RESULTS
We analyzed the proteomic profiles of the RCC tissue and
the corresponding normal kidney tissues from 7 consecutive
patients with conventional RCC. The mean age of the patients
was 65.4 yr (range 54 to 78). The tumor stage of the patients
ranged from pT1 through pT3a. The samples were examined
histologically to verify the macroscopic cell type (benign or
cancer). Necrosis was not seen in the samples. Table 1 shows
clinical and pathological features of those patients with RCC.
Spots representing proteins that were differentially expressed
in RCC were selected (p<0.05 by Student’s t-test). A total of
905 spots from a conventional RCC samples and 953 spots
from a corresponding normal kidney samples were visualized
in a gel (pH range from 4.0-7.0 and a molecular mass range
from 10-100 kDa) (Fig. 1). The overall protein expression
patterns in clear cell RCC and normal kidney tissues were
quite similar except for some areas. Ten specific regions con-
No. Sex/Age (yr) Cell type TNM stage
1 M/78 Conventional (Clear cell) T1NOMO
2 M/68 Conventional (Clear cell) T1NOMO
3 M/55 Conventional (Clear cell) T1NOMO
4 M/54 Conventional (Clear cell) T1NOMO
5 F/70 Conventional (Clear cell) T2NOMO
6 M/61 Conventional (Clear cell) T3aNOM1
7 M/72 Conventional (Clear cell) T1NOMO
Table 1. Clinical and pathological features of the patients with
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taining some proteins differentially expressed in RCC and
normal tissues were further analyzed by comparing their ex-
pression patterns in all 7 patients. For the assessment of dif-
ferentially expressed proteins only protein spots altered in
all tumor samples were considered. The protein identities
from all the spots were entered in the composite gel database
so that any changes in the protein expression could be deter-
mined for each protein spot. The integrated protein intensi-
ty was determined for each identified spot in seven gels each
from the RCC tissues and corresponding normal kidney tis-
sues. The mean intensity of each spot was calculated by its
silver stain intensity and the relative intensities between the
RCC tissues and normal tissues. Two proteins were domi-
nantly expressed in the conventional RCC and six proteins
were revealed largely repressed, these proteins were found
with a statistical significance. Some of these proteins have been
identified by mass spectrometry. A typical mass spectrum of
a protein, aldehyde reductase, is shown in Fig. 2. Total 8 pro-
teins from 11 spots were identified. The expression level of
each protein in both RCC and normal tissue was indicated by
the density values (Fig. 3, 4). Their predicted values of iso-
electrical point (pI) and molecular weight (Mw) are summa-
Fig. 1. Two-dimensional gel analysis of proteins from the conventional RCC tissue (A) and the corresponding normal kidney tissue (B).
Isoelectric focusing at pH 4-7 was carried out at the first dimension using IPG strips, and a 7.5-17.5% gradient SDS gel electrophoresis
was followed at the second dimension as described in “Materials and methods”. Numbers represent region of interest that were identi-
fied by mass spectrometry and peptide mass fingerprinting. 
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Fig. 2. Typical spectrum of Aldehyde reductase obtained from
peptide mass fingerprinting of a gel spot. After separation of the
proteins by two-dimensional gel electrophoresis, the gel spot was
excised and digested with trypsin. Peptides obtained from diges-
tion were analyzed by MALDI-TOF/mass spectrometry. The abscis-
sa represents the mass/charge ratio of ions detected in the MALDI-
TOF experiments. Peaks are almost always protonated molecular
ion [M+H
+]. The ordinate represents the relative intensity of the
averaged ion current in arbitrary units.
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Fig. 3. The intensity of protein spots (spot intensity from PDQuest
software) down-regulated in the conventional RCC samples. Dif-
ferentially expressed protein spots identified by peptide mass fin-
gerprinting are labeled with protein name. The graph shows dif-
ference of spot density as compared normal kidney tissues (closed
bar) with RCC (shaded bar). AVE, average.
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rized in Table 2, and the values were compatible to those of
acquired from the gels. The sequence coverage of proteins
isolated from the peptide mass matching in a program was
acceptable (19-55% ranges).
Several horizontal rows of spots were seen on the gel (Fig.
4). These rows of protein spots, which typically had similar
molecular sizes but slightly different isoelectrical points, prob-
ably were due to posttranslational modifications that change
in the protein charge. The protein identities from all spots
were entered in the composite gel database so that changes
in protein expression could be determined for each protein
spot. Integrated protein intensity was determined for each
identified spot in seven gels each from RCC and correspond-
ing normal kidney tissues. The mean intensity of each spot
was calculated by silver stain intensity, and relative intensi-
ties between RCC and normal tissues were compared.
Six proteins showed largely repressed expression in RCC
with a statistical significance; aminoacylase-1 in region 1,
enoyl-CoA hydratase in region 2, agmatinase and ketohex-
okinase in region 4, aldehyde reductase in region 5 and tro-
pomyosin  -4 chain in region 9 (Fig. 1, 3). Two proteins were
dominantly expressed in RCC (Fig. 1, 4);  -1 antitrypsin
precursor in region 3 and vimentin in region 7.
DISCUSSION
The proteomic approach shows great potential to be a pow-
erful tool for the identification of proteins differentially ex-
pressed in the normal kidney tissue and RCC tissue, and the
characterization of the newly isolated RCC-specific markers
might allow for a better subclassification of RCC and the early
diagnosis of this disease. In this study, 66 proteins were shown
to have either increased or decreased expression (≥2) in RCC
(data not shown). Some of these proteins have previously been
shown to have an altered expression in RCC. Among them,
five proteins were identified as vimentin (12), aminoacylase-
1, enoyl-CoA hydratase (13), aldehyde reductase (14), and
agmatinase by using MALDI-TOF mass spectrometry (15). 
Vimentin, one of the cytoskeletal proteins, was significantly
overexpressed in RCC tissue compared with the correspond-
ing normal tissue. A proteome-based study demonstrated a
heterogeneous expression pattern of vimentin in different
RCC subtypes (12). It is often associated with cellular dif-
ferentiation, invasion, migration and metastatic potential of
tumors (16).
Aminoacylase-1, which is found in many mammalian tis-
sues with the highest activities occurring in the kidney, is usu-
ally involved in detoxification processes. It hydrolyzes a variety
of N-acylated amino acids generating free amino acids and
may be involved in the synthesis of hippurate that is formed
during detoxification of aromatic compounds (17). A dimin-
ished expression of this enzyme has also been found in lung
cancer cell lines of small cell type and pulmonary tumors (18).
It is of particular importance that the gene is localized on
chromosome segment 3p21.1., a chromosome band found
altered in nearly all RCC. The von Hippel-Lindau (VHL)
gene, a tumor suppressor gene, is located on chromosome
3p25-p26 (19), and the VHL gene mutations were detected
in a high percentage of tumors from patients with conven-
tional RCC (20).
In line with the previous observation, enoyl-CoA hydratase,
a short-chain mitochondrial enoyl-CoA hydratase, involved
in mitochodrial  -oxidation, was shown to have decreased
expression in RCC (13). 
Fig. 4. The intensity of protein spots
up-regulated in the conventional RCC
samples. Differentially expressed pro-
tein spots identified by peptide mass
fingerprinting are labeled with protein
name. The graph shows difference
of spot density as compared normal
kidney tissues (closed bar) with RCC
(shaded bar).
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Sequence
coverage
Mw/pI
Mass
matched
Protein name
Accession
No.*
P01009 -1 Antitrypsin precusor 11 (42) 46737/5.4 24%
P08670 Vimentin 21 (31) 53686/5.1 49%
Q03154 Aminoacylase-1 21 (39) 45885/5.8 53%
P30084 Enoyl-CoA hydratase 16 (37) 31372/8.3 55%
P07226 Tropomyosin -4  chain 9  (25) 28522/4.7 33%
P14500 Aldehyde reductase 14 (35) 36573/6.3 50%
Q9BSE5 Agmatinase 10 (35) 37760/5.7 19%
P50053 Ketohexokinase 14 (29) 32731/5.6 19%
*Protein name and Accession number are listed according to the SWISS-
PROT database. Mw, molecular weight; pI, isoelectrical point.
Table 2. The proteins that identified by MALDI-TOF, showed dif-
ferent expression between the conventional RCC and the cor-
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Aldehyde reductase is an oxidoreductase that catalyzes
NADPH-dependent reduction of a variety of aromatic and
aliphatic aldehydes (21). This enzyme is important because
of its ability to detoxify a variety of reductive aldehyde species
and metabolize certain steroid and neurotransmitter metabo-
lites and glucuronate (22), however, little is known about its
physiological role. G250-treated and untreated RCC cell lines
were investigated for their protein expression profiles to iden-
tify tumor markers, which may allow the selection of patients
prior to specific immunotherapy. They found decreased ex-
pression of aldehyde reductase in G250-treated RCC cell line
(14). This is in line with our observation.
Recently, Dallmann et al. (15) reported that human agmati-
naes is diminished in the clear cell type of RCC by proteomic
approach. RT-PCR and Nothern blot analyses demonstrated
a clearly decreased amount of agmatinase mRNA in tumor
cells, and they confirmed the differential expression of agmati-
nase mRNA at the protein level by Western blot analysis.
The expression of agmatinase in this study was also dimin-
ished in RCC compared with that in the normal counterpart
of kidney (Fig. 3). 
-1 antitrypsin precursor, which present in the proximal
tubule of kidney, showed an increased expression in the tumor.
Based on the histochemical profile of normal kidney, carci-
noma, and oncocytoma, 89% of RCC and 50% of oncocy-
toma expressed  -1 antitrypsin activity (23).  -1 antitrypsin
is a broad spectrum inhibitor of serine proteases, including
trypsin protease, chymotrypsin protease, and elastase like
enzyme (24). Its major physiological role is the inhibition of
leukocytes elastases released at sites of inflammation. The
function of  -1 antitrypsin released by epithelial cells is still
unclear, although they may play a role in the regulation of
growth and proliferation processes. In this study, this enzyme
was overexpressed in RCC tissue, suggesting the tumor tis-
sues might need the  -1 antitrypsin activity.
A significantly heterogeneous expression pattern of the
different members of the cytoskeleton was found between
different RCC cell lines and by comparison of RCC cell lines
with corresponding kidney epithelium cell lines. Tropomyosin
-4 chain, one of the cytoskeletal proteins, showed a decreased
expression in RCC. It is noteworthy that with the exception
of cytoskeletal tropomyosin, cytoskeletal proteins seem to
be readily recognized by patients with RCC than by control
sera. The reason for the relatively high frequency of cytoskele-
tal tropomyosin autoantibodies in control sera and their poten-
tial role in the development of autoimmune disease requires
further investigation using a larger sample number (12). It
might be suggested that the loss of potential tumor antigens
over time represents an effective strategy of tumors to evade
immune recognition.
Ketohexokinase, also called fructokinase, catalyzes the phos-
phorylation of fructose to fructose1-phosphate. Much of the
ingested fructose is metabolized by the liver, using fructose
1-phosphate pathway, and then can be funneled into the uni-
versal glycolytic pathway. Although ketohexokinase is most
abundant in the liver, it is also found in the kidney, small
intestine, and pancreas (25). Glycolysis takes place predom-
inantly in the distal segments of renal tubular system. Dur-
ing the development of rat renal basophilic cell tumors, there
is a loss of gluconeogenic enzymes (26). A predominant bio-
chemical alteration in cancer cells is a markedly elevated rate
of glucose catabolism (27). Thus, it has been observed that
activities of key glycolytic enzymes such as hexokinase and
pyruvate kinase are increased in tumor cells compared with
normal cells from their tissue of origin. Nonetheless, the
increased glycolysis cannot be considered as a general phe-
nomenon in neoplasm. Some brain neoplasm, for example,
neuroblastomas (28), and retinoblastoma (29) show decreased
hexokinase activity compared with normal brain. This study
showed a decreased expression of ketohexokinase in renal
tumor tissues. However, it might also be suggested that dif-
ferent types of RCC represent different expression pattern of
ketohexokinase, which is eventually involved in glycolysis.
In conclusion, two-dimensional polyacrylamide gel elec-
trophoresis is a powerful tool to comprehensively analyze total
proteins that are differentially expressed in RCC. We com-
pared proteomes of the normal human kidney with that of
the corresponding renal cell carcinoma tissues in gels, and
identified differentially expressed proteins by mass spectrome-
try. Eight proteins from 11 spots were identified by peptide
mass fingerprinting. The expression of six proteins, amin-
noacylase-1, enoyl-CoA hydratase, aldehyde reductase, tropo-
myosin  -4 chain, agmatinase and ketohexokinase, was de-
creased in RCC. The expression of vimentin and  -1 antit-
rypsin precursor was largely increased. The study of the pro-
tein expression in RCC and the normal kidney tissue may
help us to find tumor-specific proteins of these diseases.
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